Literature DB >> 7003391

Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.

J P Kane, M J Malloy, P Tun, N R Phillips, D D Freedman, M L Williams, J S Rowe, R J Havel.   

Abstract

We studied the effect of th bite acid sequestrant colestipol, alone and in combination with clofibrate or niacin, in patients with heterozygous familial hypercholesterolemia who were given a diet low in cholesterol and saturated fat. With colestipol alone, mean cholesterol levels in serum decreased 16 to 25 per cent. The addition of clofibrate produced a total mean decrement of only 28 per cent. In contrast, serum cholesterol levels fell 45 per cent when colestipol as combined with niacin. Low-density-lipoprotein (LDL) cholesterol decreased 55 per cent with colestipol and niacin, whereas high-density-lipoprotein (HDL) cholesterol increased. Mean LDL cholesterol was lower in patients given this regimen than in matched normal controls eating an unrestricted diet. Tendinous xanthomas, measured by quantitative xeroradiography, were significantly reduced (P < 0.01), indicating that this regimen mobilized cholesterol from tissue pools with slow turnover. Colestipol plus niacin promises to be useful in the treatment of patients at high risk from elevated levels of LDL.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7003391     DOI: 10.1056/NEJM198101293040502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

Review 1.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 2.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Lipid lowering drugs.

Authors:  P O'Connor; J Feely; J Shepherd
Journal:  BMJ       Date:  1990-03-10

Review 4.  Reductase inhibitor therapy of hypercholesterolemia.

Authors:  R A Kreisberg
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

5.  Clinical and laboratory responses to niceritrol in the treatment of hypercholesterolaemia.

Authors:  L D Curtis; J P Reckless; A F Winder; D J Betteridge
Journal:  Postgrad Med J       Date:  1988-09       Impact factor: 2.401

Review 6.  Lowering cholesterol, 1988. Rationale, mechanisms, and means.

Authors:  R J Havel
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

Review 7.  Vitamin therapy in the absence of obvious deficiency. What is the evidence?

Authors:  L Ovesen
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

8.  [Relation between serum lipoprotein metabolism and biliary lipid metabolism].

Authors:  O Leiss; K von Bergmann
Journal:  Klin Wochenschr       Date:  1983-06-15

Review 9.  Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

10.  Cholesterol net transport, esterification, and transfer in human hyperlipidemic plasma.

Authors:  P E Fielding; C J Fielding; R J Havel; J P Kane; P Tun
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.